TG Therapeutics, Inc.
corporate_fare Company Profile
TG Therapeutics, Inc. (NASDAQ:TGTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for TGTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for TGTX spans 10-Q, 8-K, DEF 14A.
Recent high-impact activity:
- ENHANCE Win: Single 600mg BRIUMVI Infusion Matches Two-Dose Regimen
- TG Therapeutics Q3 2026: Revenue $259.9M, Net Income $55.5M, $556.7M Cash
- TG Therapeutics Lifts 2026 Revenue Guidance to ~$1B as BRIUMVI Grows 52%
- TG Therapeutics Posts 35c Q3 EPS as BRIUMVI Momentum Builds
- Azer-Cel Shows 89% Stable or Improved Disability Scores in Progressive MS Phase 1
Financial Snapshot
Short Interest & Short Volume
18.89 days to coverFINRA reported short interest of 28,765,675 shares in TGTX as of the October 30, 2026 settlement, a 2.8% decrease from the prior period — about 18.9 days to cover at its recent average daily volume. On November 20, 2026, 50.4% of TGTX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.